

ARTICLE INFORMATION

Author Affiliations: Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece (Sarafidis); Department of Medicine, ASH Comprehensive Hypertension Center, University of Chicago Medicine, Chicago, Illinois (Bakris).

Corresponding Author: George L. Bakris, MD, University of Chicago Medicine, 5841 S Maryland Ave, MC 1027, Chicago, IL 60637 (gbakris@gmail.com).

Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Sarafidis reports lecture fees and travel support from Novartis, lecture fees from AstraZeneca, and travel support from Daiichi Sankyo. Dr Bakris reports consultancy for AbbVie, Takeda, Medtronic, Relypsa, Daiichi Sankyo, Janssen, Novartis, and Bayer (money to his institution) and grants/grants pending from Takeda (money to his institution).

REFERENCES

- Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published online November 12, 2013]. *Circulation*. doi:10.1161/01.cir.0000437741.48606.98.
- Perry HM Jr, Miller JP, Fornoff JR, et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. *Hypertension*. 1995;25(4 pt 1):587-594.
- Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet*. 2002;360(9349):1903-1913.
- Mancia G, Fagard R, Narkiewicz K, et al; Task Force Members. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens*. 2013;31(7):1281-1357.
- James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) [published online December 18, 2013]. *JAMA*. doi:10.1001/jama.2013.284427.
- Allen N, Berry JD, Ning H, Van Horn L, Dyer A, Lloyd-Jones DM. Impact of blood pressure and blood pressure change during middle age on the remaining lifetime risk for cardiovascular disease: the cardiovascular lifetime risk pooling project. *Circulation*. 2012;125(1):37-44.
- Lee DS, Massaro JM, Wang TJ, et al. Antecedent blood pressure, body mass index, and the risk of incident heart failure in later life. *Hypertension*. 2007;50(5):869-876.
- Stewart R, Xue QL, Masaki K, et al. Change in blood pressure and incident dementia: a 32-year prospective study. *Hypertension*. 2009;54(2):233-240.
- Boshuizen HC, Lanti M, Menotti A, et al. Effects of past and recent blood pressure and cholesterol level on coronary heart disease and stroke mortality, accounting for measurement error. *Am J Epidemiol*. 2007;165(4):398-409.
- Wills AK, Lawlor DA, Matthews FE, et al. Life course trajectories of systolic blood pressure using longitudinal data from 8 UK cohorts. *PLoS Med*. 2011;8(6):e1000440.
- Wills AK, Lawlor DA, Muniz-Terrera G, et al; FALCON Study Team. Population heterogeneity in trajectories of midlife blood pressure. *Epidemiology*. 2012;23(2):203-211.
- Allen NB, Siddique J, Wilkins J, et al. Blood pressure trajectories in early adulthood and subclinical atherosclerosis in middle age. *JAMA*. doi:10.1001/jama.2013.285122.
- Franklin SS. The importance of diastolic blood pressure in predicting cardiovascular risk. *J Am Soc Hypertens*. 2007;1(1):82-93.
- Mosley WJ II, Greenland P, Garside DB, Lloyd-Jones DM. Predictive utility of pulse pressure and other blood pressure measures for cardiovascular outcomes. *Hypertension*. 2007;49(6):1256-1264.

Assessing the Trustworthiness of the Guideline for Management of High Blood Pressure in Adults

Harold C. Sox, MD

The article by James and colleagues¹ published in *JAMA* contains the long-awaited guideline for hypertension issued by the panel members appointed by the National Heart, Lung, and Blood Institute (NHLBI) to the Eighth Joint National Committee (JNC 8). In the past decade, the effect of guidelines on clinical practice has increased because organiza-

tions that develop quality measures and make coverage decisions depend on guideline developers to uncover the best evidence and make specific recommendations. **Because guidelines matter more, critics have questioned the processes that professional associations have used to develop guidelines.** The title of the 2011 Institute of Medicine (IOM) report on quality standards for practice guidelines, *Clinical Practice Guidelines We Can Trust*,² captures current concerns. Despite the efforts of the expert panel that developed the new guideline for management of hypertension, some aspects of the external review process may undermine public confidence.

The NHLBI convened the JNC 8 panel in 2008. The panel decided to adhere to the standards set by the IOM study committee² instead of following the practices of earlier JNC panels. The JNC 7 committee produced a comprehensive overview of the management of hypertension. The committee did not commission systematic reviews of the evidence. The report did not state the extent and quality of the evidence for many topics, so that the logical connection between the evidence and some recommendations was not clear. The report described conflicts of interest for committee members but did not say whether members recused themselves from voting when they had a conflict.³ As part of the guideline development process, **the present hypertension guideline panel commissioned a systematic review of randomized trial evidence, evaluated the evidence, made recommendations, indicated the level of evidence supporting those recommendations,** reported conflicts of interest, and recused conflicted panel members from voting. Because of these changes, **this guideline adheres much more closely to the IOM standards than the JNC 7 guideline.**



Editorial pages 474 and 477



Related article page 507

The external review process began when the panel submitted the draft guideline to the NHLBI. According to James et al,¹ the NHLBI submitted the guideline to 16 federal agencies and to 20 reviewers, all of whom were experts in hypertension. In addition, individual reviewers were expert in cardiology, nephrology, primary care, pharmacology, research (including clinical trials), biostatistics, and other related fields. The authors report that they received responses from 16 individual reviewers and 5 reviewers from federal agencies. The panel revised the guideline, completing its work in June 2013, just as the NHLBI announced that it was turning the guideline development process over to the American Heart Association and the American College of Cardiology, which jointly sponsor a respected guidelines program.⁴ Rather than submit the hypertension guideline for review by these organizations, the panel members submitted the guideline to *JAMA*, where it underwent both internal and external peer review.

Thus, physicians and other readers are confronted with an important report that, although it has undergone extensive review, has not been evaluated by the specialty societies that the NHLBI designated to take responsibility for the guidelines program. The panel's departure from usual practice leads to 4 questions. First, what are the key elements of trustworthiness in a guideline? Second, how does this guideline measure up? Third, what is the role of expert review of guidelines? Fourth, what is the pathway to guidelines that the public can trust?

What Are the Key Elements of a Trustworthy Guideline?

The IOM committee listed 8 standards. This editorial focuses on 4 of them. First, active management of conflict of interest is essential. The IOM committee thought that conflicts should be disclosed to the public and panelists should not vote on questions if they have a conflict. Second, a systematic review should be the starting point for developing a guideline. An IOM committee worked in parallel with the IOM guidelines committee to develop standards for systematic reviews.⁵ A systematic review should minimize the possibility that the guideline panel will fail to take account of relevant evidence. Third, the panel must explain the reasoning that led from the evidence to its recommendation. Fourth, the panel should involve relevant stakeholders in the external review process, publish a draft of the report for public comment, and record reviewer comments and the panel's response.²

Does This Guideline Pass the Test of the IOM Standards?

The committee appointed by the NHLBI met the first 3 standards with room to spare but may have fallen short of the IOM standards for external review. The published report includes important details of the review process, such as the reviewing organizations and the expertise of the reviewers. However, these hypertension guidelines, like the recently released guidelines on assessing cardiovascular risk⁶ and management of blood cholesterol,⁷ were not published in draft form to solicit public comment. These concerns notwithstanding, the committee met the first 3 standards so well that it is highly likely that the recommendations in the guideline accurately reflect strong evidence.

What Is the Role of Expert Review of Guidelines?

External reviewers may point out evidence that the committee missed, identify flawed studies, or cite illogical reasoning, poor writing, or unjustified recommendations. The credibility of a guideline depends on the thoroughness of the external reviewers and the integrity of the panel in responding to concerns. In the case of this hypertension guideline, the reader has a rare opportunity to see the review process in action and judge its integrity. The authors kept detailed records of the comments of the reviewers, the panel's responses to those comments, and how the panel considered the comments when it revised the guidelines. Remarkably, the authors have said that they will send this record to interested parties on request. This form of transparency sets an important precedent that, if adopted widely, could increase public confidence in guidelines. In this case, the record of verbatim reviewer comments and the panel's response should convince most readers that little would have been gained by additional review by specialty society-designated reviewers.

Expert review is necessary, but the review process must be managed so that unfair criticism by reviewers is exposed while the committee is held accountable for its response to credible criticism. This approach sounds difficult to achieve in practice, but one organization, the US National Academies, which includes the IOM, uses it routinely for its reports.⁸ According to the approach of this organization, good management of review should include 4 features. First, reviewers should declare all of their financial conflicts of interest. Second, the review process should be managed by an impartial organization. Third, the dialogue between reviewers and guidelines committees should distinguish evidence-based assertions from those based on opinion and personal clinical experience. This principle can help to distinguish a credible criticism from one that is suspect. Fourth, if the organization that manages the review is dissatisfied with the committee's response to reviewers' comments, it should be empowered to withhold its endorsement of the review process. The hypertension guideline committee's willingness to make public the content of the review process suggests a fifth operational principle: publish the dialogue between reviewers and guidelines committees as an online appendix to the guidelines report. This suggestion is in keeping with an overarching principle of guidelines, which is to help the health professions and the public make informed choices, not simply tell them what to do.

What Is the Pathway to Trustworthy Guidelines?

In response to the uneven quality of practice guidelines, an IOM study in 2006 proposed creating a marketplace in which guideline users can compare guidelines from different organizations.⁹ If users could identify the best-quality guidelines, they would gravitate toward them, which would compel guideline developers to raise their game or be ignored. With the publication of the GRADE standards¹⁰ and the IOM committee's quality standards,² this concept is gaining momentum. This approach requires metrics of adherence to the quality standards, which are still in the early stages of development.¹¹

A rigorous, transparent process for developing and reviewing guidelines matters a great deal because guidelines are increasingly driving the practice of medicine. This Editorial focuses on the external review process for the hypertension guideline because it raised some concerns. The panel addressed them head-on by agreeing to share its record of the review process with anyone who asks. Reading the critiques and responses, many readers will conclude that the panel was on solid ground in its interpretation of high-quality evidence about the limited but important set of questions that it chose to ad-

dress. However, a discussion of external review should include several additional questions. Should guideline users shun a guideline that has not been posted in draft form for public comment per the practice of the US Preventive Services Task Force? Have practice guidelines become so important that they require a review process managed by an impartial third party, like that used by the National Academies? The answers to those questions await public debate. Meanwhile, the panel's decision to open the review process to public scrutiny challenges other guidelines programs to follow suit.

ARTICLE INFORMATION

Author Affiliation: Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine, Hanover, New Hampshire.

Corresponding Author: Harold C. Sox, MD, Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine, 31 Faraway Ln, West Lebanon, NH 03784 (hsox@comcast.net).

Published Online: December 18, 2013.
doi:10.1001/jama.2013.284429.

Conflict of Interest Disclosures: The author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Sox reports that he was a member of the IOM committees cited in references 8 and 9 and has been a member of the Report Review Committee of the National Academies.

REFERENCES

1. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. doi:10.1001/jama.2013.284427.
2. Institute of Medicine. *Clinical Practice Guidelines We Can Trust*. Washington, DC: National Academies Press; 2011.
3. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA*. 2003;289(19):2560-2572.
4. Gibbons GH, Shurin SB, Mensah GA, Lauer MS. Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute. *Circulation*. 2013;128(15):1713-1715.
5. National Academies. Guidelines for the review of National Academies reports. http://www.nationalacademies.org/xpedio/groups/nasite/documents/webpage/na_067076.pdf. Accessed December 1, 2013.
6. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published online November 12, 2013]. *Circulation*. doi:10.1161/01.cir.0000437741.48606.98.
7. Stone NJ, Robinson J, Lichtenstein AH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published online November 12, 2013]. *Circulation*. doi:10.1161/01.cir.0000437738.63853.7a.
8. Institute of Medicine. *Finding What Works in Health Care: Standards for Systematic Reviews*. Washington, DC: National Academies Press; 2011.
9. Institute of Medicine. *Knowing What Works in Health Care: A Road Map for the Nation*. Washington, DC: National Academies Press; 2008.
10. AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. *Qual Saf Health Care*. 2003;12(1):18-23.
11. Ransohoff DF, Pignone M, Sox HC. How to decide whether a clinical practice guideline is trustworthy. *JAMA*. 2013;309(2):139-140.

Recommendations for Treating Hypertension What Are the Right Goals and Purposes?

Eric D. Peterson, MD, MPH; J. Michael Gaziano, MD; Philip Greenland, MD

Hypertension is the most common cardiovascular risk factor in the United States, affecting approximately two-thirds of adults aged 60 years or older.¹ Observational studies have demonstrated a linear relationship between blood pressure (BP) and risk of cardiovascular events. Randomized controlled trials (RCTs) have found that lowering BP by as little as 10 mm Hg in patients with hypertension can reduce a person's lifetime risk for cardiovascular and stroke death by 25% to 40%.² Yet for such a common and treatable condition, the ideal treatment goal remains uncertain—both overall and as a function of a patient's age. Compared with younger patients, older patients with hypertension are at increased risk for cardiovascular and stroke events yet are more vulnerable

to complications related to pharmacological treatment of hypertension.

The last Joint National Committee (JNC 7) Guideline, sponsored by the National Heart, Lung, and Blood Institute (NHLBI), was released more than a decade ago.³ The updated recommendations for management of high blood pressure from the panel members appointed to the JNC 8 Committee was launched 5 years ago. The process used in the most recent update differed from the prior guideline by focusing on select clinical questions that were to be answered solely using evidence from RCTs. Despite this empirical approach, the panel's summary recommendations were ultimately not sanctioned by the NHLBI. The panel's report is now published in *JAMA* as a stand-alone document,⁴ and it remains unclear as to whether, or when, or by whom another consensus national hypertension guideline will again be formulated.

←
Editorial pages 472 and 477

←
Related article page 507